Rebecca Slominski
Psychiatric/Mental Health · Omaha, NENPI 1275013112
Payments from drug & device makers
Across 129 payments — averaging $18.12 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$715
- Otsuka America Pharmaceutical, Inc.$282
- Sunovion Pharmaceuticals Inc.$173
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$169
- Alkermes, Inc.$157
- E.r. Squibb & Sons, L.L.C.$149
- plus $692 from 14 others
What the payments were for
- Food & beverage$2,29098%
- Education$472%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
How this compares
$2,337 in reported general payments places this provider in the 70th percentile of 255 psychiatric/mental health providers in Nebraska.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| AustedoDeutetrabenazine | 13 | $74,035 |
| RexultiBrexpiprazole | 42 | $62,404 |
| Invega SustennaPaliperidone Palmitate | 18 | $45,552 |
| CaplytaLumateperone Tosylate | 11 | $19,970 |
| VyvanseLisdexamfetamine Dimesylate | 19 | $7,645 |
| BelsomraSuvorexant | 11 | $4,611 |
| Duloxetine Hcl | 69 | $1,004 |
| Pregabalin | 19 | $924 |
| Atomoxetine Hcl | 15 | $832 |
| Clonazepam | 72 | $707 |
| Gabapentin | 27 | $684 |
| Quetiapine Fumarate | 20 | $589 |
| Bupropion XlBupropion Hcl | 38 | $582 |
| Dexmethylphenidate Hcl ErDexmethylphenidate Hcl | 11 | $520 |
| Divalproex Sodium ErDivalproex Sodium | 22 | $469 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Teva Pharmaceuticals USA, Inc.Austedo | $69 | $74,03513 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $282 | $62,40442 claims |
| Johnson & JohnsonInvega Sustenna | $106 | $45,55218 claims |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta | $169 | $19,97011 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Vyvanse | $69 | $7,64519 claims |
| MerckBelsomra | $26 | $4,61111 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 255 psychiatric/mental health providers in Nebraska.
Other psychiatric/mental health in Omaha
- Janelle HillOmaha$24K
- Kristi BoseOmaha$13K
- Robert LundholmOmaha$12K
- Virginia SmithOmaha$11K
- Christina HadleyOmaha$11K
- Julie ZulkoskyOmaha$8K
- John RamseyOmaha$8K
- M Joyce SasseOmaha$7K
- Molly PetersenOmaha$6K
- Salina AndersonOmaha$6K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.